In spite of its reputation as a chemosensitive malignancy, multiple myeloma remains fatal for nearly all those who contract it. The mortality has changed little in the last 30 years (Feinleib & MacMahon, 1960) , although the duration of the illness has been extended from a median of 7 months prior to the introduction of chemotherapy to around 2 years today (a figure which varies between I and 4 years depending upon the selection of patients) (Alexanian et al., 1969; Durie & Salmon, 1975; Case et al., 1977; Cooper et al., 1986) . There are, however, some signs that the situation may be changing. Recent developments in treatment intensification, maintenance therapy and newer biological approaches all suggest that in the forseeable future prolonged remissions or even cures may be obtained, particularly in selected subgroups of patients. To define these, a large number of studies examining prognostic factors have been carried out, with $-microglobulin levels (Cassuto et al., 1978; Bataille et al., 1984; Cuzick et al., 1985; Greipp et al., 1988; Dunie et al., 1990) , interleukin 6/C-reactive protein levels (Bataille et al., 1989; Ludwig et al., 1991a) , plasma cell labelling index (Durie & Bataille, 1989; Greipp et al., 1993) , lactate dehydrogenase (Dimopoulos et al., 1991) and thymidine kinase activity (Brown et al., 1993) all being used to supplement clinical information on the severity of the disease.
There remain several areas of controversy which require clarification, principally the relative merits of combination chemotherapy versus single alkylating agents with prednisolone, the place of myeloablative therapy and the role of interferon. While there is no shortage of information on conventional and interferon therapy from randomised trials, much of it is unfortunately contradictory owing to variations in patient sekction, administration of treatment and definition of responses. A particular deficit is the lack of a randomised prospective trial of treatment intensification, and the seventh Medical Research Council trial in myeloma is attempting to address this question.
The standard treatment for newly diagnosed myeloma of stages H and II has previously been the combination of an alkylating agent (melphalan or cyclophosphamide) with prednisolone given orally in short courses at monthly intervals (Alexanian et al., 1969) . With such an approach around half of the patients can be expected to show some response, the exact percentages quoted in different studies depending upon the degree of reduction in paraprotein or marrow plasmacytosis required to define a response (Rivers & Patno, 1969; MRC, 1971 MRC, , 1980 Cooper et al., 1986) . The median duration of remission is of the order of 1-2 years. Initial reports of combination chemotherapy regimens appeared to suggest that higher response rates could be achieved and survival prolonged (Case et al., 1977; Salmon et al., 1983a) . Subsequent studies have not supported this conclusion (Cooper et al., 1986; Pavlovsky et al., 1988; Peest et at., 1988; Osterborg et al., 1989; Hjorth et al., 1990) , and a recent meta-analysis of trials including nearly 4,000 patients showed no consistent benefit for combination treatments when compared with melphalan and prednisolone (Gregory et al., 1992) . However, this overall conclusion should not obscure important contributions from some combinations: a relatively small number of trials testing adriamycin-containing regimens were included in the analysis, limiting its power to detect benefits from the use of these. Patients in poor prognostic groups appeared to fare better with combination treatment (MacLennan et al., 1992) , while those with favourable features showed longer survival following melphalan and prednisolone (Peest et al., 1988; Osterborg et al., 1989) . This may relate to the faster and higher response rates which multi-drug treatments produce, an advantage more likely to benefit patients with rapid-tempo and widespread disease.
The finding that novel combinations employing infusional vincristine and adriamycin with high doses of either dexamethasone or methylprednisolone (VAD or VAMP) had significant activity in patients with disease resistant to alkylating agents (Barlogie et al., 1984; Forgeson et al., 1988) has led to these regimens increasingly being used as initial therapy. Although the remissions induced are no more durable than those following other types of conventional chemotherapy, the responses are rapid (Samson et al., 1989; Salmon & Crowley, 1992) , and the use of these treatments for cytoreduction prior to high-dose treatment with alkylating agents has the theoretical advantage of non-crossresistance.
The transience of remissions after conventional treatment has led to the investigation of dose intensification, following early work on high-dose melphalan (McElwain & Powles, 1983 (Philip et al., 1987; Gulati et al., 1988) , it is apparent that high-dose therapy is of no appreciable benefit to patients with refractory disease: although the (partial) response rates are high, the median duration of remission is consistently less than 1 year (Barlogie et al., 1986; Gobbi et al., 1989; Jagannath et al., 1990) . Similarly, in those patients in whom remission is achieved only with difficulty the results are as poor as for refractory disease (Alexanian et al., 1994) . The best results have been reported for patients receiving myeloablative treatment at the time of early first remission, with median survival times extended to over 5 years (Attal et al., 1992; Cunningham et al., 1994) .
With myeloma, unlike lymphoma, virtually all patients develop recurrent disease after high-dose therapy. Median progression-free survival is around 2 years, although regimens incorporating total body irradiation or allogeneic transplantation may yield longer disease-free intervals. Overall survival does not, however, seem to be improved (Buckner et al., 1989; Gahrton et al., 1991) . No study has formally addressed the impact of total body irradiation, but data from the French myeloma registry have suggested no benefit by comparison with chemotherapy-only regimens. The universal pattern is one of continuous recurrence with no plateau apparent in remission or survival curves. That recurrence is principally attributable to failure of the ablative treatment rather than reinfusion of viable myeloma cells is indicated by the lack of prognostic impact of marrow plasmacytosis in autologous harvests (Barlogie et al., 1986; Jagannath et al., 1990 ) and the similar pattern of recurrence following allogeneic transplant. Studies incorporating ex vivo purging of autologous bone marrow with either monoclonal antibodies or chemotherapy have not shown clarly superior results (Gobbi et al., 1989; Anderson et al., 1993; Reece et al., 1993) , and the use of peripheral blood progenitor cells seems unlikely to alter the pattern (Bell et al., 1989; Reiffers et al., 1989; Jagannath et al., 1992) . It may be that peripheral blood in any case contains myeloma precursor cells (Caligaris-Cappio et al., 1989; Cassel et al., 1990; Omede et al., 1990; Dreyfus et al., 1993) , and the theoretical possibility of promoting clonal proliferation by the use of colonystimulating factors prior to harvesting is also a matter of concern. There are other advantages to the use of peripheral blood progenitor cells, principally the reduction in the period of aplasia (Jagannath et al., 1992; , which may allow a broadening of the entry criteria for high-dose therapy, an important consideration for an illness with median age at diagnosis of 65.
The selection of patients for treatment intensification remains the crucial determinant of its efficacy. It is disturbing that myeloablative treatment is insidiously gaining acceptance as the preferred approach for younger patients without adequate testing of its validity. Preliminary data from the French collaborative trial IFM-90 are encouraging but by no means definitive. An interim analysis of the results for 150 patients randomised between completing eight cycles of conventional combination chemotherapy or receiving myeloablative therapy after four conventional treatments showed higher response rates and survival free from recurrence at a median follow-up of 30 months (data presented at British Society of Haematology conference, Harrogate, 1994) . While randomisation between two obviously disparate techniques may be difficult to explain, it must be acknowledged honestly that neither is clearly to be preferred: a similar randomisation has proven possible for the MRC trials in acute leukamia.
The limitations of chemotherapy have encouraged the investigation of biological treatments. An early report described the therapeutic effect of human leucocyte interferon in patients resistant to conventional treatment (Mellstedt et al., 1979) , and subsequent studies have confirmed responses in approximately 10% of such patients, compared with around 30% in those previously untreated (Constanzi et al., 1985; Wagstaff et al., 1985; Cooper, 1991) . An intriguing but unexplained finding is that patients with IgA myeloma appear to benefit more than others (Ohno & Kimura, 1986) . In general, the mechanism of action of interferon is poorly understood: low doses may actually stimulate the proliferation of myeloma cell lines in vitro (Klein et al., 1990) , but higher doses have direct cytotoxic activity (Creasey et al., 1980; Salmon et al., 1983; Einhorn et al., 1988) . Other possible effects include the inhibition of autocrine stimulation of myeloma cells by interleukin 6 (Jernberg-Wiklund et al., 1991) . alteration of oncogene expression (Clemens, 1985) , enhancement of tumour cell histocompatability antigen expression (Lindahl et al., 1976) and expansion of T-cell subsets (Lindahl et al., 1972; Einhorn et al., 1982) .
The incorporation of interferon into combination therapy was prompted by studies of cell lines which showed that it could enhance the cytotoxic effects of melphalan and prednisolone (Welander et al., 1985) . The results of clinical trials have been disappointing: a large randomised study by the Cancer and Leukemia Group B showed no response or survival advantage in the addition of interferon-m2b to melphalan and prednisolone (Cooper et al., 1993) . A similar-sized study by the Myeloma Group of Central Sweden showed an improved response rate using higher doses of natural interferona, although survival was only improved in patients with IgA and light-chain disease (Osterborg et al., 1993 ). An interim analysis of a randomised study of a multiagent regimen (vincristne/melphalan/cyclophosphamide/prednisolone) with or without interferon-a2b suggested a modest improvement in overall survival but with follow-up too short for reliable interpretation (Ludwig et al., 1991b ). An alternative approach has been taken by the Eastern Cooperative Group, which has reported a high response rate (80%, with 30% complete responses) using alternating cycles of vincristine/ carmustine/melphalan/cyclophosphamide/prednisolone with interferon-a2b (Oken et al., 1992) . Whether this in turn results in improved survival will be determined by trials now in progress. In general, it is difficult to be optimistic about the use of interferon in the initial treatment of myeloma.
Experimental results suggesting that interferon could reduce the proliferative capacity of myeloma cells (Salmon et al., 1983b) , and evidence from its use in chronic myeloid leukaemia that lymphoid stem cell populations might be attenuated (Bergsagel et al., 1986) led to trials of interferon as maintenance following chemotherapy. An initial report from Italy of 101 patients who were randomised to observation or interferon maintenance after 12 months' conventional chemotherapy indicated an improvement in duration of remission and of survival (from a median of 39 to 52 months), an effect confined to those in whom initial chemotherapy had produced a reduction in paraprotein of over 50% (Mandelli et al., 1990) . A similar report by the Myeloma Group of Western Sweden of 120 patients randomised after showing a reponse to conventional therapy demonstrated a prolongation of remission, albeit from an unusually low 6 months in the observation arm to 14 months (Westin et al., 1991) . No survival data have yet emerged from this study. In contrast, the Myeloma group of Central Sweden was unable to show any benefit from the addition of interferon to maintenance melphalan (Osterborg & Mellstedt, 1991) , and the Southwest Oncology Group comparing observation to interferon in 210 responding patients after combination chemotherapy found no benefit, although the follow-up was only a median 10 months (Salmon & Crowley, 1992) . The most promising data have come from studies of interferon maintenance following myeloablative therapy: a phase H study of 63 patients employing high-dose melphalan with total body irradiation and autologous bone marrow rescue before introduction of interferon yielded an 81% survival rate at 42 months from diagnosis (Fermand et al., 1993) . More recently, a randomised trial has shown improved progression-free survival following high-dose melphalan and autologous bone marrow rescue in 84 patients, with the median increased from 27 to 39 months (Cunningham et al., 1993) . The intuitive suggestion that biological treatment is most likely to be effective as maintenance therapy appears to be borne out in these studie although clearly more mature data are needed for reliable interpretation.
As an understanding of the biology of myeloma develops so newer approaches to its therapy are emerging. In particular, the identification of interleukin 6 (IL-6) as an important growth promoter in plasma cells (Zhang et al., 1989; Klein et al., 1990 ) has led to trials of anti-IL-6 blocking antibodies (Klein et al., 1991) and -tinterferon (Portier et al., 1993) or retinoic acid (Sidell et al., 1991) for down-regulation of the IL-6 receptor. The importance of multidrug resistance (MDR) gene expression is also under investigation since the observation that levels increase following chemotherapy (Dalton et al., 1989; Epstein et al., 1989; Salmon et al., 1989; Grogan et al., 1993) , although it has not always proven possible to correlate its expression with resistance to treatment (Cornelissen et al., 1994) . Attempts at sensitisation with calcium channel blockers have been disappointing (Salmon et al.. 1990) . although cyclosporin A showed some promise in early studies (Sonneveld et al.. 1992 ) and a new generation of P-glycoprotein modulators is being tested now.
The question examined in the MRC VIIth myelomatosis trial is the efficacy of two alternative approaches to treatment. In one arm intensive induction therapy with VAMP will be followed by high-dose melphalan with autologous haemopoietic stem cell support from peripheral blood or bone marrow. This will be compared with the ABCM regimen of myeloma VI. which is widely used in the UK as the standard for patients below the age of 65. Maintenance interferon is used in both arms. The trial is of flexible design and addresses both survival and quality of life. We hope that all centres which can use these approaches will join the trial to allow proper testing of powerful but potentially hazardous therapy. rather than encourage its indiscnrminate use without timely and badly needed evaluation. 
